Qiagen N.V. (QGEN)

Qiagen N.V. (NYSE: QGEN - Get Free Report) saw some unusual options trading activity on Thursday. Investors acquired 8,189 put options on the stock. This is an increase of approximately 460% compared to the average daily volume of 1,463 put options. Institutional Investors Weigh In On Qiagen Institutional investors have recently added to or reduced their

SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 3.

QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.

Qiagen N.V. (NYSE: QGEN - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors purchased 40,639 call options on the company. This is an increase of approximately 4,664% compared to the average volume of 853 call options. Key Qiagen News Here are the key news stories impacting Qiagen this

Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.64 per share a year ago.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 rose 4% to $540 million, with sales at constant exchange rates (CER) up 1% and exceeding the outlook for steady CER results compared to the year-ago period while overcoming macroeconomic challenges and the impact of the 2025 U.S. government shutdown. Solid ongoing trends among the growth pillars, which rose 7% CER,.

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN's entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo.

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (NYSE: QGEN - Get Free Report) is anticipated to release its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect Qiagen to post earnings of $0.59 per share and revenue of $528.5340 million for the quarter. Parties may review the information on the company's upcoming Q4 2025 earning report for the

QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there's renewed takeover speculation after reports that show they're weighing strategic options. QGEN's potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed.

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Ket.

German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges.

Qiagen (QGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Qiagen is weighing strategic options, including a potential sale of the diagnostics firm amid fresh takeover interest, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.